Association of plasminogen activator inhibitor-1 and fibroblastic growth factor 21 in 3 groups of type 2 diabetes: Without overweight/obesity, free of insulin resistance, and without hepatosteatosis

The physiological effects of fibroblast growth factor 21 (FGF21), leading to beneficial metabolic outcomes, have been extensively revealed in recent decades. Significantly elevated serum levels of FGF21 in obesity and type 2 diabetes mellitus (T2DM) are referred to as FGF21 resistance. However, Asia...

Descripción completa

Detalles Bibliográficos
Autores principales: Takebe, Noriko, Hasegawa, Yutaka, Matsushita, Yuriko, Chiba, Hiraku, Onodera, Ken, Kinno, Hirofumi, Oda, Tomoyasu, Nagasawa, Kan, Segawa, Toshie, Takahashi, Yoshihiko, Okada, Kenta, Ishigaki, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
4300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476825/
https://www.ncbi.nlm.nih.gov/pubmed/37657012
http://dx.doi.org/10.1097/MD.0000000000034797

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476825/
https://www.ncbi.nlm.nih.gov/pubmed/37657012
http://dx.doi.org/10.1097/MD.0000000000034797

Ejemplares similares